LU90911I2 - Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare - Google Patents

Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare

Info

Publication number
LU90911I2
LU90911I2 LU90911C LU90911C LU90911I2 LU 90911 I2 LU90911 I2 LU 90911I2 LU 90911 C LU90911 C LU 90911C LU 90911 C LU90911 C LU 90911C LU 90911 I2 LU90911 I2 LU 90911I2
Authority
LU
Luxembourg
Prior art keywords
hepacare
hepatitis
sequences
active ingredient
recombinant antigen
Prior art date
Application number
LU90911C
Other languages
English (en)
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Publication of LU90911I2 publication Critical patent/LU90911I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LU90911C 1987-06-22 2002-04-19 Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare LU90911I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP87108914 1987-06-22
EP87108915 1987-06-22
EP88109946A EP0304578B1 (fr) 1987-06-22 1988-06-22 Peptide contenant l'antigène de surface de l'hépatite B

Publications (1)

Publication Number Publication Date
LU90911I2 true LU90911I2 (fr) 2002-06-19

Family

ID=27230073

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90911C LU90911I2 (fr) 1987-06-22 2002-04-19 Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare

Country Status (3)

Country Link
EP (2) EP1088830A3 (fr)
LU (1) LU90911I2 (fr)
NL (1) NL300090I2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010300A1 (fr) * 1987-06-22 1988-12-29 Medico Labs Ag Immunogenes sous forme de particules peptidiques virales heterologues
PL168787B1 (pl) * 1989-08-03 1996-04-30 Smithkline Beecham Biolog Sposób wytwarzania czastki kompozytowej PL
EP0491077A1 (fr) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques
JP2904993B2 (ja) * 1991-10-09 1999-06-14 ロート製薬株式会社 オキシトシン受容体およびこれをコードするｄｎａ
NZ253065A (en) 1992-05-23 1996-10-28 Smithkline Beecham Biolog Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen
HU219808B (hu) 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
AT409863B (de) * 1993-07-30 2002-12-27 Immuno Ag Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält
WO1997008309A2 (fr) * 1995-08-29 1997-03-06 Immusol, Inc. Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1281761A1 (fr) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides synthetiques derivées du proteine pre-S1 de Hepatitis B virus et utilisations associées
EP1648931B1 (fr) 2003-07-21 2011-02-09 Transgene S.A. Cytokines multifonctionnelles
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2066344B2 (fr) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Vaccin combiné du virus de poliomyelite inactivé
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
EP2433648A3 (fr) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccin comprenant une émulsion adjuvante huile en l'eau
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
CA2725329C (fr) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Vaccins a nanoemulsion
WO2010141861A1 (fr) 2009-06-05 2010-12-09 Infectious Disease Research Institute Adjuvants lipidiques synthétiques à base de glucopyranosyle
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3563834A1 (fr) 2012-02-07 2019-11-06 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
EP3268037B1 (fr) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Agonistes cd27
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
CN111315362A (zh) 2017-06-15 2020-06-19 传染病研究所 纳米结构脂质载剂和稳定乳剂以及其用途
WO2019051149A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
WO2020123444A1 (fr) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Procédés d'utilisation d'anticorps cd27 en tant que traitement de conditionnement pour une thérapie cellulaire adoptive
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023077521A1 (fr) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Constructions bispécifiques anti-ilt4 et anti-pd-1
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2560890B1 (fr) * 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
EP0180012A1 (fr) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Séquence de polypeptide immunogène du virus de l'hépatite B
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (fr) * 1986-06-03 1992-11-24 Hajime Horii Promoteur de la levure et procede pour la preparation de proteines heterologues
WO1987007896A1 (fr) * 1986-06-20 1987-12-30 Scripps Clinic And Research Foundation Epitopes des cellules t et b de la region pre-s de l'antigene de surface du virus de l'hepatite b

Also Published As

Publication number Publication date
NL300090I1 (nl) 2002-07-01
EP0304578A1 (fr) 1989-03-01
EP1088830A3 (fr) 2004-04-07
NL300090I2 (nl) 2002-12-02
EP1088830A2 (fr) 2001-04-04
EP0304578B1 (fr) 2001-10-24

Similar Documents

Publication Publication Date Title
LU90911I2 (fr) Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare
OA08801A (fr) Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant.
BR9206131A (pt) Hepatite C: diagnóstico e vacinas
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
LV10726A (lv) Hepatita C virusa diagnostikas lidzekli un vakcinas
EP0550528A4 (en) Active site of interleukin-8: polypeptide analogs and antibodies
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
CY2007034I1 (el) Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
DK603888D0 (da) Rekombinant virus
GB2212511B (en) Hepatitis c virus
FR2620459B1 (fr) Virus recombinant de la vaccine
ZA831854B (en) Small peptides with the specificity of foot and mouth disease viral antigens
KR890002547A (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
EP0531365A4 (en) Diagnosis and treatment of viral hepatitis
FR2619012B1 (fr) Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
FR2689398B1 (fr) Compositions destinées au traitement de l'infection et des maladies provoquées par le virus de l'hépatite B (HBV).
NO892269D0 (no) Ikke-hyperglykosylerte hepatitt b-virus-proteiner samt ekspresjons-"kassetter" og fremgangsmaate for fremstilling avproteinene.
KR890701743A (ko) B형 간염 표면 항원 백신
IT8221787A0 (it) Procedimento per la preparazione di antigene superficiale puro dell'epatite b da plasma umano.
FR2604434B1 (fr) Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique
BR9106503A (pt) Diagnostico e tratamento de hepatite viral
JPS6471488A (en) Preparation of human immunodeficient virus type i antigen, and its use as diagnostic and curing agents
IT8886207A0 (it) La siringa contro l'epatite e l'aids
FR2563219B1 (fr) Derives d'acide n-(phenylmethylthio-3 oxo-1 propyl)- aminoacetique, leur preparation et leur application en therapeutique